Diabetic macular edema remains an important cause of vision loss among ... As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME ... approval was based on results from a clinical trial that included 634 patients ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) fell 21% today, diverging from the company's recent ...

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is being assessed in pivotal Phase 3 clinical trials to enhance the efficacy of standard anti-VEGF-A therapies.

Please provide your email address to receive an email when new articles are posted on . The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet ...

Cystoid macular edema (CME) is a condition characterized ... healthcare providers regarding this potential complication. One significant study investigated the risk of ocular adverse events ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...

Diabetic macular edema remains an important cause of visual loss among ... are currently being evaluated in randomized clinical trials. There is an emerging role for pars plana vitrectomy ...

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.